BioSyent is a high-margin, capital-light defensive compounder using FeraMAX® leadership and the Oral Science acquisition to expand from niche specialty pharmaceuticals into a broader healthcare platform with asymmetric 5-year upside.
Overview
BioSyent is a profitable Canadian specialty healthcare company that in-licenses, registers, and commercializes proven pharmaceutical, OTC, and oral-health products rather than funding risky drug discovery. Its portfolio is led by FeraMAX®, Tibella®/Tibelia®, RepaGyn®, Cathejell®, Proktis-M®, and newly acquired Oral Science dental brands. The company has delivered 63 consecutive profitable quarters, benefits from professional recommendation-driven demand, and operates with high margins, strong cash conversion, and a disciplined capital-light model.